M-HIFU was recently combined with immune checkpoint blockade in triple-negative breast cancer mice models, and this showed more potent tumor growth suppression, immunostimulatory to M1 phenotype, and increased T-cell CD8+ population compared to conventional HIFU [116]. Here, CD8A is linked to neoplasm.